Target Price | $82.63 |
Price | $61.91 |
Potential |
33.46%
register free of charge
|
Number of Estimates | 8 |
8 Analysts have issued a price target ANI Pharmaceuticals, Inc. 2026 .
The average ANI Pharmaceuticals, Inc. target price is $82.63.
This is
33.46%
register free of charge
$94.00
51.83%
register free of charge
$65.00
4.99%
register free of charge
|
|
A rating was issued by 8 analysts: 7 Analysts recommend ANI Pharmaceuticals, Inc. to buy, 1 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the ANI Pharmaceuticals, Inc. stock has an average upside potential 2026 of
33.46%
register free of charge
|
Dec '24 |
2025 Estimates |
|
---|---|---|
Revenue Million $ | 614.38 | 785.78 |
26.20% | 27.90% | |
EBITDA Margin | 11.49% | 25.48% |
48.17% | 121.83% | |
Net Margin | -3.28% | 4.24% |
203.14% | 229.28% |
8 Analysts have issued a sales forecast ANI Pharmaceuticals, Inc. 2025 . The average ANI Pharmaceuticals, Inc. sales estimate is
This results in the following potential growth metrics:
7 Analysts have issued an ANI Pharmaceuticals, Inc. EBITDA forecast 2025. The average ANI Pharmaceuticals, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
4 ANI Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2025. The average ANI Pharmaceuticals, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Dec '24 |
2025 Estimates |
|
---|---|---|
Earnings Per Share $ | -1.04 | 1.54 |
222.35% | 248.08% | |
P/E | 40.27 | |
EV/Sales | 2.30 |
4 Analysts have issued a ANI Pharmaceuticals, Inc. forecast for earnings per share. The average ANI Pharmaceuticals, Inc. EPS is
This results in the following potential growth metrics and future valuations:
ANI Pharmaceuticals, Inc....
Analyst | Rating | Action | Date |
---|---|---|---|
Guggenheim |
Locked
➜
Locked
|
Locked | May 12 2025 |
Truist Securities |
Locked
➜
Locked
|
Locked | Apr 21 2025 |
Guggenheim |
Locked
➜
Locked
|
Locked | Apr 11 2025 |
HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 17 2025 |
Jefferies |
Locked
➜
Locked
|
Locked | Mar 14 2025 |
JP Morgan |
Locked
➜
Locked
|
Locked | Mar 12 2025 |
Guggenheim |
Locked
➜
Locked
|
Locked | Mar 05 2025 |
Analyst Rating | Date |
---|---|
Locked
Guggenheim:
Locked
➜
Locked
|
May 12 2025 |
Locked
Truist Securities:
Locked
➜
Locked
|
Apr 21 2025 |
Locked
Guggenheim:
Locked
➜
Locked
|
Apr 11 2025 |
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 17 2025 |
Locked
Jefferies:
Locked
➜
Locked
|
Mar 14 2025 |
Locked
JP Morgan:
Locked
➜
Locked
|
Mar 12 2025 |
Locked
Guggenheim:
Locked
➜
Locked
|
Mar 05 2025 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.